Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 14951 - 14959 of 14959 in total
EVT 201 is a novel partial positive allosteric modulator of the GABAA receptor complex which is being developed as a treatment for insomnia. It is being developed by Evotec Inc.
Investigational
TAK-475 is a "squalene synthase inhibitor", a type of cholesterol-lowering drug that has not yet been brought to market.
Investigational
VLTS-589 consists of plasmid encoding the angiomatrix protein Del-1 in conjunction with poloxamer 188 for the treatment of peripheral vascular disease.
Investigational
99mTc-glucarate(GLA) is an agent for non-invasive detection of breast tumours.
Investigational
Eprodisate slows the decline of renal function in AA amyloidosis.
Investigational
ETC-1001 is Pfizer’s lead oral small molecule product candidate which is intended to be a chronic treatment for individuals with lipid disorders.
Investigational
Denibulin is a novel small molecule Vascular Disrupting Agent under development by MediciNova for treatment of solid tumor cancers.
Investigational
AEOL 10150 is developed by Aeolus as a therapeutic agents based on its proprietary small molecule catalytic antioxidants.
Investigational
Rimtuzalcap is a novel modulator of small-conductance calcium-activated potassium channels that is under investigation for the treatment of essential tremor.
Investigational
Displaying drugs 14951 - 14959 of 14959 in total